Company profile: Gliknik
1.1 - Company Overview
Company description
- Provider of therapies for patients with cancer and immune disorders, including recombinant Fc fusion proteins in clinical trials: GL-2045, aimed at treating autoimmune diseases by mimicking IVIG effects, and GL-0719, designed to selectively inhibit the classical and lectin complement pathways for autoimmune disease treatment.
Products and services
- GL-0719: Investigational recombinant Fc fusion protein engineered to selectively inhibit classical and lectin complement pathways for autoimmune disease treatment
- GL-2045: Clinical-stage recombinant Fc fusion protein that mimics the effects of IVIG to treat autoimmune diseases
- Cancer and Immune Disorder Therapies: Patient-directed development of therapies for patients with cancer and immune disorders
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Gliknik
Theravectys
HQ: France
Website
- Description: Provider of a proprietary lentiviral vector platform for developing vaccines and immunotherapies to prevent and treat infectious diseases, cancers, and other conditions. Pipeline includes Lenti-HPV-07 (Phase 1) for HPV16/18-induced oropharyngeal and cervical cancers, Lenti-COVID intranasal vaccine for SARS-CoV-2 variants, and LV-DEN tetravalent T-cell dengue vaccine. Initial clinical focus includes HIV/AIDS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theravectys company profile →
Abcuro
HQ: United States
Website
- Description: Provider of immunotherapies for autoimmunity and cancer, including ABC008, a monoclonal antibody targeting KLRG1 to selectively deplete highly cytotoxic T cells in inclusion body myositis, T-cell large granular lymphocytic leukemia, and certain cancers, and ABC015, a preclinical antibody blocking KLRG1-ligand interaction to activate cytotoxic T and NK cells; conducts clinical trials for ABC008 in IBM and T-LGLL.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abcuro company profile →
Curevo Vaccine
HQ: United States
Website
- Description: Provider of next-generation, non-mRNA vaccines for infectious diseases, developing Amezosvatein for the prevention of shingles and chickenpox.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Curevo Vaccine company profile →
Celldex Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage antibody-based therapeutics, including monoclonal and bispecific antibodies, targeting inflammatory, allergic, autoimmune, and other severe diseases. Pipeline includes barzolvolimab (KIT inhibitor for mast cell-driven diseases) and CDX-585 (PD-1/ILT4 bispecific for solid tumors). Services include conducting clinical trials and offering compassionate use/expanded access programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celldex Therapeutics company profile →
SAB Biotherapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies and platform technologies, including SAB-142 for modulating the immune over-response in Type 1 Diabetes; SAB-176, a fully human polyclonal antibody for treatment and post-exposure prophylaxis of pandemic and seasonal influenza in high-risk patients; the DiversitAb platform for producing fully human, multi-targeted immunoglobulins without donors; and an Expanded Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SAB Biotherapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Gliknik
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Gliknik
2.2 - Growth funds investing in similar companies to Gliknik
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Gliknik
4.2 - Public trading comparable groups for Gliknik
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →